anti-MPL (MPL) Antikörper

anti-Myeloproliferative Leukemia Virus Oncogene Antikörper (MPL)
Auf finden Sie aktuell 63 Myeloproliferative Leukemia Virus Oncogene (MPL) Antikörper von 11 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen MPL Proteine (21) und MPL Kits (2) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 89 MPL Produkte verfügbar.
C-MPL, c-mpl-I, c-mpl-II, CD110, hlb219, MPL, MPLV, THCYT2, TPO-R, TPOR

Meistgesuchte Reaktivitäten zu anti-MPL (MPL) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Human MPL Antikörper:

anti-Mouse (Murine) MPL Antikörper:

anti-Rat (Rattus) MPL Antikörper:

Alle verfügbaren anti-MPL Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-MPL Antikörper

  1. Human Monoclonal MPL Primary Antibody für FACS, WB - ABIN967682 : Broudy, Lin, Fox, Taga, Saito, Kaushansky: Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. in Blood 1996 (PubMed)
    Zeige alle 4 Referenzen für 967682

  2. Human Monoclonal MPL Primary Antibody für EIA, FACS - ABIN1105749 : Raposo, Sousa, Kirsch, Cardoso, Belsley, de Matos Gomes, Fonseca: Synthesis and characterization of dicyanovinyl-substituted thienylpyrroles as new nonlinear optical chromophores. in Organic letters 2006 (PubMed)
    Zeige alle 2 Referenzen für 1105749

  3. Human Monoclonal MPL Primary Antibody für FACS, ELISA - ABIN969542 : Marty, Chaligné, Lacout, Constantinescu, Vainchenker, Villeval: Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. in The Journal of biological chemistry 2009 (PubMed)
    Zeige alle 2 Referenzen für 969542

Weitere Antikörper gegen MPL Interaktionspartner

Human Myeloproliferative Leukemia Virus Oncogene (MPL) Interaktionspartner

  1. these results demonstrate that MPL P106L is a receptor with an incomplete defect in trafficking.

  2. Coexisting mutations of the JAK2 (zeige JAK2 Antikörper), CALR (zeige CALR Antikörper), and MPL genes in myeloproliferative neoplasms suggest that CALR (zeige CALR Antikörper) and MPL should be analyzed not only in JAK2 (zeige JAK2 Antikörper)-negative patients but also in low V617F mutation patients.

  3. identification of a higher frequency of co-existing JAK2 (zeige JAK2 Antikörper) exon-12 or MPL exon-10 mutations in patients with myeloproliferative neoplasms with a low JAK2V617F allelic burden compared to those with a higher allelic burden.

  4. A newborn girl with congenitcal amegakaryocytic thrombocytopenia had a homozygous missense Trp154-to- Arg mutation in exon 4 of c-MPL. The same heterozygote mutation was detected in her mother, father, and 2 siblings.

  5. Mutation status of JAK2 (zeige JAK2 Antikörper), CALR (zeige CALR Antikörper), and MPL in essential thrombocythemia and primary myelofibrosis defines clinical outcome.

  6. Normal FLT3 (zeige FLT3 Antikörper) and negative expression of CD34 (zeige CD34 Antikörper) and cMPL may predict a longer overall survival in aute myeloid leukemia (zeige BCL11A Antikörper).

  7. we show that the positive charge of the CALR (zeige CALR Antikörper) mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between mutant CALR (zeige CALR Antikörper) and the thrombopoietin receptor MPL.

  8. Anagrelide proved effective among all molecular subsets, indicating that JAK2 (zeige JAK2 Antikörper)/CALR (zeige CALR Antikörper)/MPL mutational status does not seem to represent a major determinant of choice of cytoreductive treatment among essential thrombocythemia therapies.

  9. In essential thrombocythemia, MPL mutations might be associated with a higher risk of fibrotic transformation and the presence of JAK2 (zeige JAK2 Antikörper)/MPL mutations with higher risk of thrombosis.

  10. PARP-1 (zeige PARP1 Antikörper) has an important role in the progression of acute myeloid leukemia (zeige BCL11A Antikörper) by suppressing the myeloproliferative leukemia virus oncogene

Mouse (Murine) Myeloproliferative Leukemia Virus Oncogene (MPL) Interaktionspartner

  1. these results demonstrate that MPL P106L is a receptor with an incomplete defect in trafficking.

  2. C-Mpl is expressed on osteoblasts and osteoclasts and is important in regulating skeletal homeostasis.

  3. CALR (zeige CALR Antikörper) mutants are sufficient to induce thrombocytosis through MPL activation.

  4. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin (zeige CALR Antikörper) mutants.

  5. The interaction between Mpl and Atp5d (zeige ATP5D Antikörper) was confirmed by the yeast two-hybrid system, mammalian two-hybrid assay, pull-down experiment, and co-immunoprecipitation study in vivo and in vitro.

  6. Mouse prenatal platelet-forming lineages share a core transcriptional program but divergent dependence on MPL.

  7. MERIT40 (zeige BABAM1 Antikörper) deficiency triggers hypersensitivity to Tpo (zeige THPO Antikörper) stimulation and the stem cell phenotypes are abrogated on a background null for the Tpo (zeige THPO Antikörper) receptor Mpl.

  8. OTT1 regulates the alternative splicing of Mpl-TR, a truncated isoform of c-Mpl, which modulates Thrombopoietin (zeige THPO Antikörper)-mediated signaling.

  9. Mpl expression, but not Tpo (zeige THPO Antikörper), is fundamental in the development of JAK2V617F(+) myeloproliferative neoplasms

  10. Thrombopoietin (zeige THPO Antikörper)/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 (zeige MECOM Antikörper) leukemia.

MPL Antigen-Profil

Beschreibung des Gens

In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

Alternative names and synonyms associated with MPL

  • myeloproliferative leukemia virus oncogene (MPL) Antikörper
  • myeloproliferative leukemia virus oncogene (LOC100230798) Antikörper
  • myeloproliferative leukemia virus oncogene (LOC100355135) Antikörper
  • myeloproliferative leukemia virus oncogene (Mpl) Antikörper
  • C-MPL Antikörper
  • c-mpl-I Antikörper
  • c-mpl-II Antikörper
  • CD110 Antikörper
  • hlb219 Antikörper
  • MPL Antikörper
  • MPLV Antikörper
  • THCYT2 Antikörper
  • TPO-R Antikörper
  • TPOR Antikörper

Bezeichner auf Proteinebene für MPL

thrombopoietin receptor , myeloproliferative leukemia virus oncogene , thrombopoietin receptor-like , TPO-R , myeloproliferative leukemia protein , proto-oncogene c-Mpl

414804 Gallus gallus
528492 Bos taurus
723813 Macaca mulatta
747522 Pan troglodytes
100008643 Oryctolagus cuniculus
100066544 Equus caballus
100230798 Taeniopygia guttata
100355135 Oryctolagus cuniculus
100448006 Pongo abelii
100626347 Sus scrofa
4352 Homo sapiens
17480 Mus musculus
366455 Rattus norvegicus
Ausgewählte Anbieter für anti-MPL (MPL) Antikörper
Haben Sie etwas anderes gesucht?